Pressreleases

Marina Biotech and Girindus Group Announce Strategic Alliance

Marina Biotech, Inc. (OTCQX:MRNA), a leading nucleic acid-based drug discovery and development company and Girindus Group today announced that they have entered into a strategic alliance where Girindus will have exclusive rights to develop, supply and commercialize certain oligonucleotide constructs using Marina’s Conformationally Restricted Nucleotide (CRN) chemistry and in return, Marina will receive royalties from the sale of CRN-based oligonucleotide reagents as well as a robust supply of cGMP material for Marina and its partners’ pre-clinical, clinical and commercialization needs.